Intellia Therapeutics, Inc. (NASDAQ: NTLA)

$14.28 ▲ +0.29 (+2.07%)

As of May 13, 2026 03:59 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001652130

Market Cap 1.69 Bn

P/E -4.05

P/S 25.64

Div. Yield 0.00

Add ratio to table...

About

Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on developing CRISPR-based therapies to address serious genetic diseases. The company leverages its proprietary CRISPR/Cas9 platform and delivery technologies to create in vivo and ex vivo therapeutic candidates that target the root cause of diseases. Its core activities involve researching, developing, and advancing product candidates through preclinical and clinical stages with the goal of delivering potentially curative treatments for patients with high unmet...

Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on developing CRISPR-based therapies to address serious genetic diseases. The company leverages its proprietary CRISPR/Cas9 platform and delivery technologies to create in vivo and ex vivo therapeutic candidates that target the root cause of diseases. Its core activities involve researching, developing, and advancing product candidates through preclinical and clinical stages with the goal of delivering potentially curative treatments for patients with high unmet medical needs.

The company generates revenue primarily through collaboration agreements, including upfront technology access payments, research funding, milestone payments, and cost reimbursements from collaborators. All revenue to date has been derived from these collaborative arrangements, with no product sales revenue reported as of the filing date. Key collaborators include Regeneron Pharmaceuticals, Inc., with whom Intellia co-develops and co-promotes its ATTR amyloidosis program, as well as other partners such as ONK and Kyverna under separate agreements.

The company operates through the following segments:

• In Vivo Therapeutics.

• Ex Vivo Therapeutics.

Intellia Therapeutics, Inc. is positioned as a pioneer in the clinical development of systemic CRISPR-based therapies, with its lead programs lonvo-z and nex-z representing the first CRISPR-based treatments administered via intravenous infusion for in vivo gene editing in humans. The company competes with other gene editing and genetic medicine companies such as CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics, as well as traditional RNAi and protein-based therapy developers in the HAE and ATTR amyloidosis markets. Its competitive advantages include a modular platform enabling rapid program expansion, deep expertise in delivery technologies like lipid nanoparticles, a strong intellectual property portfolio, and clinical-stage validation of durable therapeutic effects from single-dose treatments.

The company serves patients suffering from severe genetic diseases, including those with hereditary angioedema and transthyretin amyloidosis, as well as individuals with immuno-oncology and autoimmune conditions targeted by its ex vivo programs. Specific customer names are not disclosed in the filing, as the business model relies on therapeutic development and future commercialization rather than direct sales to identifiable clients at this stage.

Investment thesis

Bull case

Intellia’s one‑time gene‑editing platform remains uniquely positioned to transform a series of orphan diseases that traditionally require chronic, high‑cost therapies. The ATTRv‑PN program, now cleared by the FDA to resume enrollment, is poised to generate early revenue streams through a first‑in‑class treatment that offers durable disease modification with a single infusion. The timing of the regulatory lift aligns with the company’s cash runway, allowing it to sustain operations through the anticipated data readout in the second half of 2026 and to prepare for a commercial launch in the first half of 2027. The company’s balanced capital structure, with roughly $670 million in cash and a readily available ATM facility, underpins this aggressive pipeline strategy and gives it breathing room to absorb the cost of the ongoing ATTR‑CM hold without immediate liquidity pressure.
The company’s focus on the ATTR‑CM indication, despite the current hold, offers a far larger commercial opportunity than the ATTRv‑PN program alone. While the heart‑related form of amyloidosis has a more aggressive disease trajectory and a higher unmet need, the potential market size is considerably larger, encompassing a broader patient population that is already underserved by existing therapies. Intellia’s data indicating a less than 1% incidence of Grade 4 liver enzyme elevations among over 650 patients provides a reassuring safety signal that may be persuasive to regulators once a robust mitigation plan is articulated. The company’s proactive engagement with the FDA, as evidenced by the clinical hold, demonstrates a willingness to cooperate and adapt, which could translate into a favorable risk–benefit assessment if the hold is lifted.
Lonvo‑z, the one‑time treatment for hereditary angioedema, has already completed enrollment and is on track to deliver topline results in mid‑2026. The therapeutic benefit of completely eliminating attacks would be a paradigm shift for a patient group that currently relies on episodic, costly therapies. With the company’s extensive experience in the ATTR platform, the manufacturing scale‑up and supply chain logistics for Lonvo‑z can likely be leveraged, reducing time‑to‑market costs. The company’s recent collaboration revenue increase, driven primarily by a partnership with a major biopharma, underscores its capacity to monetize data assets and potentially secure additional licensing revenue.
Intellia’s choice of a lipid‑nanoparticle (LNP) delivery system that is common across both nex‑z and lonvo‑z indicates an opportunity for platform synergies. By reusing the same delivery vehicle, the company can potentially lower manufacturing complexity and reduce regulatory hurdles associated with novel delivery components. This consolidation can translate into cost efficiencies, improving gross margins once the drugs enter the commercial phase. Moreover, the shared LNP platform may enable cross‑indication data sharing, which could accelerate the development timeline for future programs targeting other monogenic diseases.
The company's emphasis on the high mortality of ATTR amyloidosis signals a robust market narrative that resonates with payers and clinicians alike. By framing the therapy as a life‑extending intervention, Intellia aligns its value proposition with reimbursement models that prioritize durable outcomes over incremental symptom control. This positioning is likely to strengthen payer negotiations, especially in markets where chronic therapies are heavily scrutinized for cost effectiveness. The narrative also enhances investor confidence, as it underscores a clear differentiation from existing treatments that merely slow disease progression.

Intellia’s one‑time gene‑editing platform remains uniquely positioned to transform a series of orphan diseases that traditionally require chronic, high‑cost therapies. The ATTRv‑PN program, now cleared by the FDA to resume enrollment, is poised to generate early revenue streams through a first‑in‑class treatment that offers durable disease modification with a single infusion. The timing of the regulatory lift aligns with the company’s cash runway, allowing it to sustain operations through the anticipated data readout in the second half of 2026 and to prepare for a commercial launch in the first half of 2027. The company’s balanced capital structure, with roughly $670 million in cash and a readily available ATM facility, underpins this aggressive pipeline strategy and gives it breathing room to absorb the cost of the ongoing ATTR‑CM hold without immediate liquidity pressure.
The company’s focus on the ATTR‑CM indication, despite the current hold, offers a far larger commercial opportunity than the ATTRv‑PN program alone. While the heart‑related form of amyloidosis has a more aggressive disease trajectory and a higher unmet need, the potential market size is considerably larger, encompassing a broader patient population that is already underserved by existing therapies. Intellia’s data indicating a less than 1% incidence of Grade 4 liver enzyme elevations among over 650 patients provides a reassuring safety signal that may be persuasive to regulators once a robust mitigation plan is articulated. The company’s proactive engagement with the FDA, as evidenced by the clinical hold, demonstrates a willingness to cooperate and adapt, which could translate into a favorable risk–benefit assessment if the hold is lifted.
Lonvo‑z, the one‑time treatment for hereditary angioedema, has already completed enrollment and is on track to deliver topline results in mid‑2026. The therapeutic benefit of completely eliminating attacks would be a paradigm shift for a patient group that currently relies on episodic, costly therapies. With the company’s extensive experience in the ATTR platform, the manufacturing scale‑up and supply chain logistics for Lonvo‑z can likely be leveraged, reducing time‑to‑market costs. The company’s recent collaboration revenue increase, driven primarily by a partnership with a major biopharma, underscores its capacity to monetize data assets and potentially secure additional licensing revenue.
Intellia’s choice of a lipid‑nanoparticle (LNP) delivery system that is common across both nex‑z and lonvo‑z indicates an opportunity for platform synergies. By reusing the same delivery vehicle, the company can potentially lower manufacturing complexity and reduce regulatory hurdles associated with novel delivery components. This consolidation can translate into cost efficiencies, improving gross margins once the drugs enter the commercial phase. Moreover, the shared LNP platform may enable cross‑indication data sharing, which could accelerate the development timeline for future programs targeting other monogenic diseases.
The company's emphasis on the high mortality of ATTR amyloidosis signals a robust market narrative that resonates with payers and clinicians alike. By framing the therapy as a life‑extending intervention, Intellia aligns its value proposition with reimbursement models that prioritize durable outcomes over incremental symptom control. This positioning is likely to strengthen payer negotiations, especially in markets where chronic therapies are heavily scrutinized for cost effectiveness. The narrative also enhances investor confidence, as it underscores a clear differentiation from existing treatments that merely slow disease progression.

Bear case

The fatal liver event in the ATTR‑CM trial, coupled with the subsequent FDA clinical hold, raises a significant safety red flag that could erode confidence among regulators, clinicians, and payers. Even though the incidence of Grade 4 liver enzyme elevations is less than 1% in a large cohort, the severity of the event and the lack of a definitive causal link to the therapy may trigger extended scrutiny and more stringent post‑market surveillance requirements. The company’s evasive answers regarding comorbidities and potential causative factors may suggest insufficient data transparency, further unsettling stakeholders.
The persistence of the hold on the ATTR‑CM program, while the ATTRv‑PN trial proceeds, creates a discontinuity in the company’s pipeline that can dilute investor expectations. The ATTR‑CM indication, representing a larger market, remains in regulatory limbo, potentially postponing a substantial revenue stream that could have justified the company’s valuation. The uncertainty surrounding a viable mitigation plan increases the probability of a protracted hold or even a partial or full withdrawal from the market.
The company’s ability to recover from the hold is heavily dependent on the outcome of the comprehensive safety analysis, which is currently inconclusive. The risk that the FDA may demand additional pre‑clinical studies, or impose stringent post‑approval monitoring requirements, could increase development costs and delay commercial launch. In the worst case, regulatory action could compel the company to halt the ATTR‑CM program entirely, leading to a loss of investment and potential reputational damage.
Intellia’s cash runway, while sufficient until mid‑2027, is subject to the unpredictability of the ATTR‑CM hold and the time needed to complete additional trials or remedial actions. The company’s financial statements show a decline in R&D expenses but still record substantial operational costs that could be exacerbated by the hold. If the company cannot secure additional financing or partnerships, it may be forced to cut back on other pipeline programs, limiting future growth opportunities.
The competitive landscape for ATTR amyloidosis is intensifying, with multiple players already offering or developing therapies that target the same patient populations. Alnylam’s injectable Amvuttra, Pfizer’s Vyndaqel, and BridgeBio’s Attruby represent significant market entrants with established clinical data, marketing pipelines, and payer relationships. Intellia’s potential delay in launching ATTR‑CM may allow competitors to capture market share, diminishing the commercial viability of its therapy.

The fatal liver event in the ATTR‑CM trial, coupled with the subsequent FDA clinical hold, raises a significant safety red flag that could erode confidence among regulators, clinicians, and payers. Even though the incidence of Grade 4 liver enzyme elevations is less than 1% in a large cohort, the severity of the event and the lack of a definitive causal link to the therapy may trigger extended scrutiny and more stringent post‑market surveillance requirements. The company’s evasive answers regarding comorbidities and potential causative factors may suggest insufficient data transparency, further unsettling stakeholders.
The persistence of the hold on the ATTR‑CM program, while the ATTRv‑PN trial proceeds, creates a discontinuity in the company’s pipeline that can dilute investor expectations. The ATTR‑CM indication, representing a larger market, remains in regulatory limbo, potentially postponing a substantial revenue stream that could have justified the company’s valuation. The uncertainty surrounding a viable mitigation plan increases the probability of a protracted hold or even a partial or full withdrawal from the market.
The company’s ability to recover from the hold is heavily dependent on the outcome of the comprehensive safety analysis, which is currently inconclusive. The risk that the FDA may demand additional pre‑clinical studies, or impose stringent post‑approval monitoring requirements, could increase development costs and delay commercial launch. In the worst case, regulatory action could compel the company to halt the ATTR‑CM program entirely, leading to a loss of investment and potential reputational damage.
Intellia’s cash runway, while sufficient until mid‑2027, is subject to the unpredictability of the ATTR‑CM hold and the time needed to complete additional trials or remedial actions. The company’s financial statements show a decline in R&D expenses but still record substantial operational costs that could be exacerbated by the hold. If the company cannot secure additional financing or partnerships, it may be forced to cut back on other pipeline programs, limiting future growth opportunities.
The competitive landscape for ATTR amyloidosis is intensifying, with multiple players already offering or developing therapies that target the same patient populations. Alnylam’s injectable Amvuttra, Pfizer’s Vyndaqel, and BridgeBio’s Attruby represent significant market entrants with established clinical data, marketing pipelines, and payer relationships. Intellia’s potential delay in launching ATTR‑CM may allow competitors to capture market share, diminishing the commercial viability of its therapy.

Consolidation Items Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	QNTM	Quantum Biopharma Ltd.	925,748.71 Bn	0.68	-	-
2	LEGN	Legend Biotech Corp	2,886.00 Bn	-4.05	2,805.37	0.32 Bn
3	EVAX	Evaxion A/S	1,751.45 Bn	0.00	47.33	-
4	VRTX	Vertex Pharmaceuticals Inc / Ma	115.93 Bn	29.31	9.66	-
5	REGN	Regeneron Pharmaceuticals, Inc.	74.80 Bn	16.90	5.01	1.99 Bn
6	ALNY	Alnylam Pharmaceuticals, Inc.	38.74 Bn	76.91	9.04	-
7	RVMD	Revolution Medicines, Inc.	28.52 Bn	-25.25	-	-
8	BNTX	BioNTech SE	27.82 Bn	-19.84	15.02	0.41 Bn

Research Tools